medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 6

<< Back Next >>

Ann Hepatol 2015; 14 (6)

Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas

Chun S, Rhie SY, Ki Chang-Seok, Kim JE, Park Hyung-Doo

Language: English
References: 23
Page: 881-888
PDF size: 102.45 Kb.


ABSTRACT

The objective of this study was to establish modified cutoff values of serum alpha-fetoprotein (AFP) according to hepatitis status. While AFP is used as a serum marker in the diagnosis or monitoring of hepatocellular carcinoma (HCC), its use as a screening method to the general population is controversial. We evaluated its screening performance in a hepatitis prevalent East Asian population, and suggest different cutoff values according to the individual’s hepatitis status. We evaluated the performance of AFP as a screening test in 48,123 consecutive Koreans during the period from March, 2012 to August, 2013 who underwent routine health checks at a single institution. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated with fixed cutoff and with modified cutoffs according the individual’s hepatitis status. A total of 24 out of 48,123 subject (0.05%) were newly diagnosed with HCC after screening. Among the 1,874 subject with positive hepatitis B virus surface antigen (HBsAg), 17 (0.91%) developed HCC, compared with two out of 393 (0.51%) individuals with hepatitis C virus antibody (anti-HCV). Five out of 45,855 (0.01%) subject with neither HBsAg nor anti-HCV developed HCC. Compared to the performance of a fixed cutoff, specificity, PPV, and NPV improved without sacrificing sensitivity when applying modified cutoff. In conclusion, our findings suggest that AFP with modified cutoffs according to the individual’s hepatitis status might be a useful screening marker for HCC in hepatitis prevalent areas.


REFERENCES

  1. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 2013; 45: 1-14.

  2. Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol 2009; 15(Suppl. 6): S13-S24.

  3. Kim do Y, Kim IH, Jeong SH, Cho YK, Lee JH, Jin YJ, Lee D, et al. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int 2013; 33: 586-94.

  4. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372-80.

  5. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-33.

  6. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.

  7. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001; 34: 603-5.

  8. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.

  9. Ball D, Rose E, Alpert E. Alpha-fetoprotein levels in normal adults. Am J Med Sci 1992; 303: 157-9.

  10. Sizaret P, Martel N, Tuyns A, Reynaud S. Mean alpha-fetoprotein values of 1,333 males over 15 years by age groups. Digestion 1977; 15: 97-103.

  11. El-Bahrawy M. Alpha-fetoprotein-producing non-germ cell tumours of the female genital tract. Eur J Cancer 2010; 46: 1317-22.

  12. Liu X, Cheng Y, Sheng W, Lu H, Xu Y, Long Z, Zhu H, et al. Clinicopathologic features and prognostic factors in alpha- fetoprotein-producing gastric cancers: analysis of 104 cases. J Surg Oncol 2010; 102: 249-55.

  13. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-8.

  14. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2012; 107: 64-74.

  15. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005; 43: 434-41.

  16. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.

  17. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, Zhu YR. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003; 10: 204-9.

  18. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-22.

  19. Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-5.

  20. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 1175-81.

  21. Tateyama M, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, Abiru S, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 2011; 46: 92-100.

  22. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007; 37(Suppl. 2): S88-S94.

  23. Chen L, Zhao H, Yang X, Gao JY, Cheng J. HBsAg-negative hepatitis B virus infection and hepatocellular carcinoma. Discov Med 2014; 18: 189-93.




2020     |     www.medigraphic.com